Aclaris Therapeutics Inc (ACRS) News

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

This Healthcare Stock Soared Following Exclusive License Agreement Announcement

A healthcare company based out of Pennsylvania caused quite the stir on Tuesday after the company announced that it had entered into an exclusive...

Form 3 - Initial statement of beneficial ownership of securities

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology...

Form 8-K - Current report

Aclaris Therapeutics Announces $80 Million Private Placement

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or...

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

- Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

– First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage...